Æterna Zentarisの推定成長EPS Q/Q
Æterna Zentarisの推定成長EPS Q/Qは何ですか。
Æterna Zentaris, Inc.の推定成長EPS Q/Qは82.61%です。
推定成長EPS Q/Qの定義は何ですか。
期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
TSXのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べるÆterna Zentaris
Æterna Zentarisは何をしますか。
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Æterna Zentarisと類似の推定成長eps q/q
- Grasim Industriesの推定成長EPS Q/Qは81.81%です。
- OrthoPediatrics corpの推定成長EPS Q/Qは81.82%です。
- Dnow Incの推定成長EPS Q/Qは81.82%です。
- Lumax Industriesの推定成長EPS Q/Qは81.99%です。
- Freehold Royaltiesの推定成長EPS Q/Qは82.35%です。
- Canadian Solar Incの推定成長EPS Q/Qは82.35%です。
- Æterna Zentarisの推定成長EPS Q/Qは82.61%です。
- Boise Cascade Coの推定成長EPS Q/Qは82.68%です。
- Norbordの推定成長EPS Q/Qは82.76%です。
- TCFの推定成長EPS Q/Qは83.33%です。
- DBV Technologiesの推定成長EPS Q/Qは83.33%です。
- Gildan Activewear Incの推定成長EPS Q/Qは83.33%です。
- TCF Corpの推定成長EPS Q/Qは83.33%です。